There are definitely phenotypical variations in humans that have health implications. To the extent that some of these are adaptive to region they may align with the rather poorly defined buckets we call ‘race’.

To GP’s point, lack of diversity in clinical trials can result in medicines that vary in efficacy and safety in the broader population. The ability to customize a therapy to an individual would help reduce the impact of this issue.